Experimental Drug DNL343 Fails to Slow ALS Progression in Randomized Trial
A randomized clinical trial in JAMA Network Open found that 200 mg per day of DNL343, an eIF2B activator, did...
Diana Fleming is a Scienmag editorial specialist profile for Neurodegenerative Diseases coverage.
A randomized clinical trial in JAMA Network Open found that 200 mg per day of DNL343, an eIF2B activator, did...
Injecting tau filaments from Alzheimer's and corticobasal degeneration patients into wild-type mice induces endogenous tau pathologies with identical folded structures,...
New research shows that alpha-synuclein, best known for its role in Parkinson's disease, enters macrophages through the protein FLOT1, blocks...
A community study of 339 cognitively unimpaired older adults found that motor speech features from self-administered rapid syllable repetition tasks...
A new study finds that whole-blood mitochondrial DNA copy number, but not telomere length, clearly distinguishes Parkinson's disease from multiple...
By stratifying Parkinson's patients into mouse-model-anchored immune subtypes, researchers have built T-cell receptor blood tests that exceed 0.8 AUC, overturning...
A new PPMI analysis shows that combining a blood-based microRNA-7-5p measurement with the alpha-synuclein seed amplification assay can identify prodromal...
A new review in Nature Reviews Neurology argues that defective lysosomal function is a central, genetically validated driver of Parkinson...
A French research team has developed DiaSeg, a framework that extracts diagonal segments from Dynamic Time Warping paths to create...
New research shows that deleting or blocking the immune receptor FcγRIIb dramatically impairs the spread of alpha-synuclein pathology in the...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine